Factors associated with first- and second-line attrition among metastatic breast cancer patients

被引：0
|
作者：
Blondeaux, Eva
Boni, Luca
Chila, Giovanna
Dri, Arianna
Caputo, Roberta
Poggio, Francesca
Fabi, Alessandra
Arpino, Grazia
Pravisano, Federico
Geuna, Elena
Ruelle, Tommaso
Giannubilo, Irene
de Laurentiis, Michelino
Puglisi, Fabio
Bighin, Claudia
Lambertini, Matteo
Montemurro, Filippo
Del Mastro, Lucia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-06-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-06-01
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
    Kristen D. Whitaker
    Xiaoliang Wang
    Mustafa Ascha
    Timothy N. Showalter
    Heather G. Lewin
    Gregory S. Calip
    Lori J. Goldstein
    Breast Cancer Research and Treatment, 2022, 196 : 163 - 173
  • [22] Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
    Whitaker, Kristen D.
    Wang, Xiaoliang
    Ascha, Mustafa
    Showalter, Timothy N.
    Lewin, Heather G.
    Calip, Gregory S.
    Goldstein, Lori J.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (01) : 163 - 173
  • [23] Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
    Petracci, Elisabetta
    Scarpi, Emanuela
    Passardi, Alessandro
    Biggeri, Annibale
    Milandri, Carlo
    Vecchia, Stefano
    Gelsomino, Fabio
    Tassinari, Davide
    Tamberi, Stefano
    Bernardini, Ilaria
    Accettura, Caterina
    Frassineti, Giovanni Luca
    Amadori, Dino
    Nanni, Oriana
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [24] Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Lin, Nancy U.
    Parker, Leroy M.
    Come, Steven E.
    Burstein, Harold J.
    Haldoupis, Margaret
    Ryabin, Nicole
    Gelman, Rebecca
    Winer, Eric P.
    Shulman, Lawrence N.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (04) : 369 - 375
  • [25] Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
    Procopio, Giuseppe
    Derosa, Lisa
    Gernone, Angela
    Morelli, Franco
    Sava, Teodoro
    Zustovich, Fable
    De Giorgi, Ugo
    Ferrari, Vittorio
    Sabbatini, Roberto
    Gasparro, Donatello
    Felici, Alessandra
    Burattini, Luciano
    Calvani, Nicola
    Lo Re, Giovanni
    Banna, Giuseppe
    Brizzi, Maria Pia
    Rizzo, Mimma
    Ciuffreda, Libero
    Iacovelli, Roberto
    Ferrau, Francesco
    Taibi, Eleonora
    Bracarda, Sergio
    Porta, Camillo
    Galligioni, Enzo
    Contu, Antonio
    FUTURE ONCOLOGY, 2014, 10 (10) : 1741 - 1750
  • [26] Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Nancy U. Lin
    Leroy M. Parker
    Steven E. Come
    Harold J. Burstein
    Margaret Haldoupis
    Nicole Ryabin
    Rebecca Gelman
    Eric P. Winer
    Lawrence N. Shulman
    Investigational New Drugs, 2007, 25 : 369 - 375
  • [27] Cost Utility in Second-Line Metastatic Breast Cancer
    Gilles Berdeaux
    Patrick Hurteloup
    PharmacoEconomics, 1997, 11 : 492 - 495
  • [28] Capecitabine second-line monotherapy for metastatic breast cancer
    Vasev, N.
    Maneva, L.
    Smickoska, S.
    Arsovski, O.
    Stojkovski, I.
    Milanova, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 133 - 134
  • [29] Cost utility in second-line metastatic breast cancer
    Berdeaux, G
    Hurteloup, P
    PHARMACOECONOMICS, 1997, 11 (05) : 492 - 495
  • [30] Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial
    Boccia, R. V.
    Vaughn, L.
    Zeigler, H.
    Wang, Y.
    Gill, J.
    Melemed, A.
    Shonukan, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345